2-methyl-5-(toluene-4-sulfonyl)-4,6-dihydro-5H-pyrrolo<3,4-d>thiazole | 170456-89-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methyl-5-(toluene-4-sulfonyl)-4,6-dihydro-5H-pyrrolo<3,4-d>thiazole
• 英文别名: 2-methyl-5-tosyl-5,6-dihydro-4H-pyrrolo[3,4-d]thiazole；2-methyl-5-[(4-methylphenyl)sulfonyl]-5,6-dihydro-4H-pyrrolo[3,4-d][1,3]thiazole；2-methyl-5-(4-methylphenyl)sulfonyl-4,6-dihydropyrrolo[3,4-d][1,3]thiazole
• CAS: 170456-89-0
• 化学式: C₁₃H₁₄N₂O₂S₂
• 分子量: 294.398
• InChiKey: LXEXKPBPYDTHBJ-UHFFFAOYSA-N

物化性质

• 沸点：
  462.6±55.0 °C(Predicted)
• 密度：
  1.387±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  86.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-methyl-5-(toluene-4-sulfonyl)-4,6-dihydro-5H-pyrrolo<3,4-d>thiazole 在 氢溴酸 、 苯酚 作用下， 反应 1.0h， 以77%的产率得到2-甲基-5,6-二氢-4H-吡咯并[3,4-d][1,3]噻唑氢溴酸
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of 1-Cyclopropyl-6,8-difluoro-7-(2-substituted 4,6-dihydro-1H-pyrrolo[3,4-d]thiazol-5-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic Acid

  摘要：

  Quinolone derivatives (9 and 10) substituted with bicyclothiazole (7) and (8) at C-7 position were synthesized. Bicyclothiazole derivatives (7 and 8) were prepared through 9 steps by way of the 4-bromo-3-oxopyrrolidine (16) was a key intermediate and introduced into the title compounds as new C-7 substituents. In vitro antibacterial activity of 9 and 10 was also reported.

  DOI：

  10.3987/com-94-6916
• 作为产物：
  描述：

  4-溴-1-[(4-甲基苯基)磺酰基]吡咯烷-3-酮 在 甲基磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 2-methyl-5-(toluene-4-sulfonyl)-4,6-dihydro-5H-pyrrolo<3,4-d>thiazole
  参考文献：
  名称：

  [EN] HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
  [FR] COMPOSÉS [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES À SUBSTITUTION HÉTÉROBICYCLIQUE AYANT DES PROPRIÉTÉS D'ANTAGONISTES DU RÉCEPTEUR A2A

  摘要：

  揭示了Formula Gl（结构表示如下）的化合物：其中“RG3”、“Rd1”至“Rd4”、“n”、“m”、“p”、“W”、“X”、“Y”和“Z”在此处被定义，这些化合物是A2A受体的拮抗剂。本文还披露了所述化合物作为A2a受体拮抗剂在潜在的治疗或预防涉及A2A受体的神经系统疾病和疾病中的用途。本文还披露了包含这些化合物的药物组合物以及这些药物组合物的用途。

  公开号：

  WO2014105666A1

文献信息

• [EN] HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER<br/>[FR] COMPOSÉS HÉTÉROBICYCLO-SUBSTITUÉS-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE POUR LE TRAITEMENT D'UN TROUBLE DU SYSTÈME NERVEUX CENTRAL
  申请人：MERCK SHARP & DOHME

  公开号：WO2014101373A1

  公开（公告）日：2014-07-03

  Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A-receptor.

  本文披露了异杂双环取代的[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物，其具有对A2A受体的特异结合，并可用于定量各种具有与A2A受体结合亲和力的化合物在体内受体位点的占有率。
• [EN] HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES<br/>[FR] COMPOSÉS [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES À SUBSTITUTION HÉTÉROBICYCLIQUE AYANT DES PROPRIÉTÉS D'ANTAGONISTES DU RÉCEPTEUR A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2014105666A1

  公开（公告）日：2014-07-03

  Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

  揭示了Formula Gl（结构表示如下）的化合物：其中“RG3”、“Rd1”至“Rd4”、“n”、“m”、“p”、“W”、“X”、“Y”和“Z”在此处被定义，这些化合物是A2A受体的拮抗剂。本文还披露了所述化合物作为A2a受体拮抗剂在潜在的治疗或预防涉及A2A受体的神经系统疾病和疾病中的用途。本文还披露了包含这些化合物的药物组合物以及这些药物组合物的用途。
• Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
  申请人：Biftu Tesfaye

  公开号：US20090270467A1

  公开（公告）日：2009-10-29

  The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式（I）的新型取代氨基环己烷，其是二肽基肽酶-IV酶的抑制剂，并且对于涉及二肽基肽酶-IV酶的疾病的治疗或预防，例如糖尿病，特别是2型糖尿病，具有用途。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及二肽基肽酶-IV酶的疾病中的使用。
• Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07750034B2

  公开（公告）日：2010-07-06

  The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种结构式为（I）的新型取代氨基环己烷，其为二肽基肽酶-IV酶的抑制剂，可用于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的用途。
• HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
  申请人：ALI Amjad

  公开号：US20150361098A1

  公开（公告）日：2015-12-17

  Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

  本文披露了G1式化合物（结构式表示）：其中“RG3”、“Rd1”至“Rd4”、“n”、“m”、“p”、“W”、“X”、“Y”和“Z”在此定义，这些化合物是A2A受体的拮抗剂。本文还披露了所述化合物作为A2A受体拮抗剂在潜在的涉及A2A受体的神经系统疾病的治疗或预防中的用途。本文还披露了包含这些化合物的制药组合物和这些制药组合物的用途。